0001562180-21-006476.txt : 20211015
0001562180-21-006476.hdr.sgml : 20211015
20211015183345
ACCESSION NUMBER: 0001562180-21-006476
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211015
FILED AS OF DATE: 20211015
DATE AS OF CHANGE: 20211015
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Linetsky David
CENTRAL INDEX KEY: 0001776729
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38977
FILM NUMBER: 211326987
MAIL ADDRESS:
STREET 1: C/O PHREESIA, INC.
STREET 2: 432 PARK AVENUE S., 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phreesia, Inc.
CENTRAL INDEX KEY: 0001412408
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0131
BUSINESS ADDRESS:
STREET 1: 434 FAYETTEVILLE ST.
STREET 2: SUITE 1400
CITY: RALEIGH
STATE: NC
ZIP: 27601
BUSINESS PHONE: 646-747-9959
MAIL ADDRESS:
STREET 1: 434 FAYETTEVILLE ST.
STREET 2: SUITE 1400
CITY: RALEIGH
STATE: NC
ZIP: 27601
FORMER COMPANY:
FORMER CONFORMED NAME: Phreesia Inc
DATE OF NAME CHANGE: 20070914
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-10-15
false
0001412408
Phreesia, Inc.
PHR
0001776729
Linetsky David
C/O PHREESIA, INC.
434 FAYETTEVILLE ST., SUITE 1400
RALEIGH
NC
27601
false
true
false
false
SVP, Life Sciences
Common Stock
2021-10-15
4
M
false
5452.00
4.71
A
145840.00
D
Common Stock
2021-10-15
4
S
false
5452.00
65.3584
D
140388.00
D
Stock Option
4.71
2021-10-15
4
M
false
5452.00
0.00
D
2028-01-30
Common Stock
5452.00
11851.00
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.67 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
Allison Hoffman, as Attorney-in-Fact for David Linetsky
2021-10-15